PMID- 34262345
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220424
IS  - 1179-1322 (Print)
IS  - 1179-1322 (Electronic)
IS  - 1179-1322 (Linking)
VI  - 13
DP  - 2021
TI  - A Comparison of Adverse Events Among Radiofrequency Ablation, Conventional 
      Transarterial Chemoembolization (TACE) and Drug-Eluting Bead TACE in Treating 
      Hepatocellular Carcinoma Patients.
PG  - 5373-5382
LID - 10.2147/CMAR.S308097 [doi]
AB  - BACKGROUND: There has been very limited investigation regarding the comparison of 
      adverse events (AEs) among radiofrequency ablation (RFA), conventional 
      transarterial chemoembolization (cTACE), and drug-eluting bead TACE (DEB-TACE) in 
      treating HCC patients; therefore, the present study aimed to resolve this issue. 
      METHODS: Two-hundred and forty-six HCC patients (with a total of 267 procedures 
      [treatment times]) treated with RFA (73 patients with 79 procedures), cTACE (86 
      patients with 94 procedures), or DEB-TACE (87 patients with 94 procedures) were 
      included. Demographic and clinical data were collected. The information on AEs 
      was also retrieved and analyzed. RESULTS: Total AEs incidence was notably 
      different among the RFA group, cTACE group, and DEB-TACE group and was the 
      highest in cTACE group (86.2%), then in DEB-TACE group (76.6%), and the lowest in 
      RFA group (63.3%). Regarding specific AEs incidence, the incidences of fever, 
      fatigue, and nausea were distinctive among the three groups, while no 
      distinctiveness was found in incidence of other AEs. Furthermore, multivariate 
      logistic regression revealed that cTACE (versus RFA) was independently correlated 
      with increased risk of total AEs, fatigue, and nausea/vomiting; however, the 
      interventional therapies were not independently correlated with the risk of pain, 
      fever or constipation. Other independent predictive factors for total AEs risk 
      were male gender, bronchial asthma, and disease duration. CONCLUSION: cTACE 
      resulted in the highest AEs incidence compared with RFA and DEB-TACE in treating 
      HCC patients.
CI  - (c) 2021 Cao et al.
FAU - Cao, Guangshao
AU  - Cao G
AD  - Department of Intervention, Henan Provincial People's Hospital, People's Hospital 
      of Zhengzhou University, People's Hospital of Henan University, Zhengzhou, Henan, 
      People's Republic of China.
FAU - Liu, Yuyan
AU  - Liu Y
AD  - Department of Intervention, Henan Provincial People's Hospital, People's Hospital 
      of Zhengzhou University, People's Hospital of Henan University, Zhengzhou, Henan, 
      People's Republic of China.
FAU - Li, Lupeng
AU  - Li L
AD  - Department of Intervention, Henan Provincial People's Hospital, People's Hospital 
      of Zhengzhou University, People's Hospital of Henan University, Zhengzhou, Henan, 
      People's Republic of China.
FAU - Zhao, Xiaoyang
AU  - Zhao X
AD  - Department of Intervention, Henan Provincial People's Hospital, People's Hospital 
      of Zhengzhou University, People's Hospital of Henan University, Zhengzhou, Henan, 
      People's Republic of China.
FAU - Liu, Ruiqing
AU  - Liu R
AD  - Department of Intervention, Henan Provincial People's Hospital, People's Hospital 
      of Zhengzhou University, People's Hospital of Henan University, Zhengzhou, Henan, 
      People's Republic of China.
FAU - Liu, Jian
AU  - Liu J
AD  - Department of Intervention, Henan Provincial People's Hospital, People's Hospital 
      of Zhengzhou University, People's Hospital of Henan University, Zhengzhou, Henan, 
      People's Republic of China.
FAU - Liu, Jianwen
AU  - Liu J
AD  - Department of Intervention, Henan Provincial People's Hospital, People's Hospital 
      of Zhengzhou University, People's Hospital of Henan University, Zhengzhou, Henan, 
      People's Republic of China.
FAU - Cao, Huicun
AU  - Cao H
AD  - Department of Intervention, Henan Provincial People's Hospital, People's Hospital 
      of Zhengzhou University, People's Hospital of Henan University, Zhengzhou, Henan, 
      People's Republic of China.
LA  - eng
PT  - Journal Article
DEP - 20210705
PL  - New Zealand
TA  - Cancer Manag Res
JT  - Cancer management and research
JID - 101512700
PMC - PMC8275035
OTO - NOTNLM
OT  - adverse events
OT  - conventional transarterial chemoembolization
OT  - drug-eluting bead transarterial chemoembolization
OT  - hepatocellular carcinoma
OT  - radiofrequency ablation
COIS- The authors declare that they have no conflicts of interest.
EDAT- 2021/07/16 06:00
MHDA- 2021/07/16 06:01
PMCR- 2021/07/05
CRDT- 2021/07/15 06:17
PHST- 2021/02/23 00:00 [received]
PHST- 2021/06/11 00:00 [accepted]
PHST- 2021/07/15 06:17 [entrez]
PHST- 2021/07/16 06:00 [pubmed]
PHST- 2021/07/16 06:01 [medline]
PHST- 2021/07/05 00:00 [pmc-release]
AID - 308097 [pii]
AID - 10.2147/CMAR.S308097 [doi]
PST - epublish
SO  - Cancer Manag Res. 2021 Jul 5;13:5373-5382. doi: 10.2147/CMAR.S308097. eCollection 
      2021.